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Abstract Four women with childhood-onset steroid-sen-
sitive nephrotic syndrome (SSNS) had 5 pregnancies. Their
age at onset of SSNS was between 4 and 10 years, and age
at pregnancy was between 21 and 31 years. Three patients
with frequent relapsing nephrotic syndrome (NS) continued
to relapse after 20 years of age. Two of them had relapses
during 6–32 gestational weeks of pregnancy and were
treated with prednisolone (PSL) 10–45 mg/day. One
patient delivered a normal baby on 2 pregnancies. Another
developed superimposed preeclampsia and her infant
showed asymmetrical type of intrauterine growth restric-
tion (IUGR). There was no relapse during pregnancy in 2
patients, including 1 with frequent relapses, who had no
relapse over 5 years preceding the pregnancy. In all four
patients, normal renal function and complete remission
were noted at the last follow-up. Their 5 infants were well
at 1–7 years of age. Although hypertension, growth failure
of the placenta, and IUGR of the baby may complicate the
pregnancy, most pregnancies with SSNS seem to result in
normal birth, even when relapses occur during pregnancy
and are treated with PSL.
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Introduction
Few reports of pregnancy in women with childhood-onset
steroid-sensitive nephrotic syndrome (SSNS) are available.
According to earlier reports by Makker and Heymann [1],
Murai et al. [2], and Kosino et al. [3], termination of
pregnancy was recommended when nephrotic syndrome
(NS) recurred in a pregnant mother, because of poor
prognosis of the fetus. The clinical course of pregnancy in
both childhood-onset SSNS and adulthood-onset SSNS
seems to be similar [1, 3]. In this paper, 3 pregnancies
which were complicated with relapse of SSNS resulted in
live birth and favorable outcome in patients with SSNS.
Progress of treatment for NS, obstetrical management, and
perinatal care may change the management of pregnancy in
patients with SSNS [4, 5].
Case report
Four women with SSNS conceived 5 babies. Table 1 shows
the profiles of the 4 mothers with SSNS and their newborn
babies. NS was diagnosed in patients who had heavy pro-
teinuria (more than 40 mg/m2 per hour) and hypoalbumi-
nemia (serum albumin\2.5 g/dL). Patients who responded
during 8 weeks of prednisolone (PSL) treatment were
defined as SSNS. Relapse was defined as a reappearance of
proteinuria (2? or greater by dipstick for 3 consecutive
days). Frequent relapses were defined as two or more
relapses within the first 6 months after initial response or
four or more relapses during any 12-month period [6].
Estimated glomerular filtration rate was calculated by
method of Matsuo et al. [7]. Their age at onset of NS was
between 4 and 10 years. Hypertension, hematuria, or renal
failure was not noted in these 4 patients, and the diagnosis of
O. Motoyama (&)
Department of Pediatrics, Toho University Medical Center,




Naruse Renal Clinic, Tokyo, Japan
123
CEN Case Rep (2014) 3:63–67
DOI 10.1007/s13730-013-0087-9
minor glomerular abnormalities was confirmed by renal
biopsy in 3 patients (cases 2–4). The number of relapses of
NS was between 4 and 77, and frequent relapsing NS was
noted in 3 patients (cases 1–3). They were treated with PSL,
combined with cyclophosphamide in 2 patients (cases 2 and
3), cyclosporine (CyA) in 3 (cases 1–3), and mizoribine in 1
(case 2). Cyclophosphamide at a dose of 2 mg/kg for
8–12 weeks and mizoribine at a dose of 100 mg/m2 were
used before 14 years of age. Two patients (cases 3 and 4),
who had no relapse for more than 5 years before pregnancy,
had no relapse during pregnancy and had normal term
deliveries. However, case 4 developed a fourth relapse
1 year after the delivery. Relapse occurred within 2 years
prior to pregnancy in cases 1 and 2. The 2 patients had
relapse during pregnancy. Case 1 had a relapse during her
first and second pregnancies and case 2 had three relapses.
Five infants were born alive. Four infants were delivered at
term and were appropriate birth weights for their gestational
ages, and one showed an intrauterine growth restriction
(IUGR). In all four mothers, normal renal function and
complete remission of NS were noted at the last follow-up,
when they were between 24 and 33 years of age. Their 5
infants were well at 1–7 years of age and congenital mal-
formation was not noted among them.
Clinical findings, gestational weeks, and treatment for
relapse of NS during pregnancy are shown in Tables 2 and 3.
Case 1
Case 1 had been treated with PSL 30 mg/day at the last
relapse before the pregnancy. She was treated with PSL on
alternate days with 5 mg at the onset of relapse during her
first pregnancy. At relapse, when she was at 10 weeks of
gestation during her first pregnancy, methylprednisolone
500 mg was administered intravenously, followed by oral
PSL 20 mg/day. PSL was gradually tapered to 10 mg/day
at 20 weeks of gestation and was maintained during
pregnancy. Relapse during her second pregnancy occurred
5 months after PSL was discontinued. At relapse, when she
was at 7 weeks of gestation, PSL was started at a dose of
45 mg/day. PSL was gradually reduced to 10 mg/day at
22 weeks of gestation and was maintained during preg-
nancy. Proteinuria disappeared within 1 week after the start
of PSL in these relapses. After remission of NS, her blood
pressure remained normal. The birth weights of infants and
placenta (650 and 670 g, respectively) were normal in both
deliveries.
Table 1 Profiles of 4 mothers with childhood-onset steroid-sensitive nephrotic syndrome (SSNS) and their newborn babies
Case 1 Case 2 Case 3 Case 4
Nephrotic syndrome
Age at onset 10 years 4 years 5 years 4 years
Renal biopsy finding ND MCNS MCNS MCNS
Number of relapses 44 77 26 4
Treatment PSL, CyA PSL, CY, MZ, CyA PSL, CY, CyA PSL
Interval between pregnancy and the last relapse 1st: 9 months
2nd: 1 years
8 months 6 years 5 years




Age 1st: 26 years
2nd: 31 years
27 years 31 years 21 years
Gestational age 1st: 40 weeks
2nd: 38 weeks
38 weeks 40 weeks 40 weeks




Age 33 years 28 years 33 years 24 years
Blood pressure (mmHg) 120/70 122/78 110/70 110/70
Serum creatinine (mg/dL) 0.5 0.6 0.6 0.5
eGFR (mL/min/1.73 m2) 113 105 90 137
Proteinuria – – – –
ND not done, MCNS minimal change nephrotic syndrome, PSL prednisolone, CyA cyclosporine, CY cyclophosphamide, MZ mizoribine, AGA
appropriate-for-gestational-age infant, SGA small-for-gestational-age infant, eGFR estimated glomerular filtration rate
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Case 2
Case 2 had been treated with PSL 20 mg/day at the
last relapse before the pregnancy. She was treated with
PSL 7.5 mg/day and CyA 150 mg/day (trough level
69–94 ng/mL) at 6 weeks of gestation. At relapse, she was
treated with PSL 20 mg/day and proteinuria disappeared a
week later. After PSL was reduced to 12.5 mg/day at
8 weeks of gestation, the second relapse occurred at
22 weeks of gestation. She was treated with PSL 30 mg/day.
Proteinuria disappeared 3 weeks after the second relapse.
After PSL was reduced to 17.5 mg/day at 28 weeks of ges-
tation, the third relapse occurred. She had no edema and was
treated with PSL 20 mg/day until delivery. After the third
relapse at 32 weeks of gestation, proteinuria continued until
delivery and her serum albumin was 2.5 g/dL at delivery.
Fetal ultrasonography showed impaired fetal growth from
30 weeks of gestation and oligohydramnios after
36 weeks, but did not reveal any fetal malformations. She
developed hypertension (142/92 mmHg) at bed rest at
38 weeks of gestation. Labor was induced by oxytocin
injection and she delivered a female infant with an Apgar
score of 9 and 9 at 1 and 5 min, respectively. Her body
weight was 2171 g (below the 10th percentile for the
Japanese population), body length was 41.7 cm (below the
10th percentile), and head circumference was 32.5 cm
(above the 10th percentile). Small placenta (377 g) with
no signs of chorioamnionitis or infarct of the placenta was
noted. She had asymmetrical type of IUGR due to pla-
cental insufficiency and superimposed preeclampsia. After
birth, she developed no complications and was discharged
at 12 days of age. CyA was discontinued 2 weeks before
delivery and breast-feeding was started after delivery. One
month later, hypertension was resumed. Two months later,
Table 2 Clinical findings and treatment at relapse of nephrotic syndrome (NS) during pregnancy in case 1
First pregnancy Second pregnancy
Relapse Delivery Relapse Delivery
Gestational weeks 10 20 40 7 22 38
Blood pressure (mmHg) 156/90 126/80 118/80 136/70 110/60 NA
Edema ? - - - - -
Total protein (g/dL) 5.0 5.9 ND 6.5 ND ND
Albumin (g/dL) 2.4 3.2 ND 3.6 ND ND
Creatinine (mg/dL) 0.5 0.4 ND 0.6 ND ND
Proteinuriaa 3? – – 3? – –
Treatment
PSL (mg/day) 20 10 10 45 10 10
Time to induce remission 4 days 6 days
NA not available, ND not done, PSL prednisolone
a Degree of proteinuria detected by dipstick was graded as: 3?, 300 mg/dL
Table 3 Clinical findings and treatment at relapse of nephrotic syndrome (NS) during pregnancy in case 2
First relapse Second relapse Third relapse Delivery
Gestational weeks 6 8 22 28 32 36 38
Blood pressure v(mmHg) 144/90 128/80 130/84 134/80 134/86 140/90 142/92
Edema - - - - - - ?
Total protein (g/dL) ND ND 6.5 6.4 6.1 6.2 5.8
Albumin (g/dL) ND ND 3.1 3.0 2.3 2.8 2.5
Creatinine (mg/dL) ND ND 0.4 0.3 0.4 0.4 0.3
Proteinuriaa 2? - 3? - 3? 3? 3?
Treatment
PSL (mg/day) 20 12.5 30 17.5 20 20 20
CyA (mg/day) 150 125 75 75 50 25 0
Time to induce remission 1 weeks 3 weeks 10 weeks
ND not done, PSL prednisolone, CyA cyclosporine
a Degree of proteinuria detected by dipstick was graded as: 2?, 100 mg/dL; 3?, 300 mg/dL
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breast-feeding resumed. After delivery, 3 relapses occur-
red and CyA was restarted.
Discussion
The effects of pregnancy on preexisting chronic kidney
disease depend on the type of renal disease, the level of
renal impairment, and the presence of hypertension. The
prognosis of pregnancy in women with chronic kidney
disease is thought to be good when their serum creatinine
and blood pressure are normal [4]. Few reports of preg-
nancy in women with childhood-onset SSNS are available.
Usually, relapse of SSNS during pregnancy does not occur
after long-term remission prior to pregnancy [1, 3, 8].
Pregnancy dose not seem to be a trigger causing relapse of
NS and does not affect the natural history of minimal
change NS [9]. Favorable prognosis of pregnancy within
remission of SSNS has been reported. On the other hand,
maternal severe proteinuria or hypoproteinemia may result
in small-for-gestational-age infants [9]. Pregnant women
with chronic kidney disease administered immunosup-
pressive drugs present the problems of an increased inci-
dence of abortion, preterm delivery, IUGR, and low birth
weight infants [10]. Some reports [1–3] have recommended
termination of pregnancy when NS recurred in a pregnant
mother, because of poor prognosis of the fetus.
Immunosuppressive drugs cross the placental barrier
and enter the fetal circulation. PSL crosses the placenta and
66 % of PSL is metabolized into inactive prednisone by the
placental 11-beta-hydroxysteroid dehydrogenase [10].
There was no sign of adrenal insufficiency in the fetus [2,
11]. PSL or CyA may inhibit placental growth and pla-
cental insufficiency seemed to increase IUGR. CyA also
crosses the placenta. A suppression of T, B, and NK cells in
infants exposed to maternal CyA may continue up to 1 year
of age. CyA is excreted into breast milk and breast-feeding
is not recommended while taking CyA because of its
immunosuppressive effect in infants. CyA was discontin-
ued 2 weeks before delivery in case 2. Cyclophosphamide
and mizoribine are contraindicated during pregnancy
because of fatal toxicity [10].
In our patients who had long-term remission of SSNS,
pregnancy did not lead to relapse. The Japanese Society of
Nephrology recommends pregnancy in women with NS after
a remission period lasting longer than 6 months after the
treatment was discontinued. Women of childbearing age
who continue to relapse frequently during adulthood, as in
cases 1 and 2 in this study, do not achieve remission without
treatment. Among 110 children with SSNS who were treated
at Toho University Medical Center, Omori Hospital (Tokyo,
Japan) and Sakura Hospital between 1972 and 2005, 7
patients continued to relapse after 20 years of age and one
was 34 years old when he had the last relapse [12]. Obstet-
rical management and perinatal care has progressed since the
earlier reports published between 1972 and 1985 [1–3].
Neonatal mortality of low birth weight infants (\2500 g) in
Japan continues to decrease from 8.8 % in 1980 and 4.8 % in
1990 to 2.4 % in 2000 [13]. Although hypertension, growth
failure of the placenta due to PSL and CyA, and IUGR due to
hypoproteinemia [9] may be complicated in some cases,
most women with SSNS seem to have successful pregnan-
cies, even when they had relapse during pregnancy and were
treated with PSL [4, 11]. Chen et al. [11] also reported
favorable outcome of pregnancy in 6 women presenting NS
with normal renal function during pregnancy and who were
treated with PSL. Their renal biopsy showed lupus nephritis
in 3 patients, mesangial proliferative glomerulonephritis in
2, and endocapillary proliferative glomerulonephritis in 1.
They were treated with intravenous methylprednisolone 1 g
for 3 consecutive days, followed by oral PSL 0.5 mg/kg/day
for 8 weeks or oral PSL 1 mg/kg/day for 8 weeks after
20 weeks of pregnancy. Five term infants were appropriate
weights for gestational ages and an infant who weighed
1900 g was small for gestational age. The clinical course of
these 6 mothers after delivery was good.
Case 1 presented with edema at relapse during her first
pregnancy. A high dose of methylprednisolone was used to
achieve remission and to maintain fetal circulation, as early
as possible. PSL 45 mg/day was started at relapse during
her second pregnancy. At both relapses, she went into
remission early and delivered a normal baby. Case 2
developed relapse without edema and was treated with PSL
20 mg/day. When superimposed preeclampsia occurred at
the third trimester of pregnancy, close follow-up by obste-
tricians and induced labor at an appropriate period resulted
in the successful delivery of a small-for-gestational-age
infant. There is no protocol of treatment for relapse of SSNS
during pregnancy. The dose of PSL should be determined
individually to induce remission in each relapse during
pregnancy according to the treatment of previous relapse.
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